A phase 1b study of isatuximab and bendamustine for triple-class refractory multiple myeloma
Clinical Lymphoma, Myeloma & Leukemia(2023)
关键词
refractory multiple myeloma,multiple myeloma,isatuximab,bendamustine,triple-class
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要